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Although cough and sputum production may impact patients’ well being and functioning in
COPD and chronic bronchitis, there is no validated instrument for cough and sputum symptoms
and their impact on patients’ daily activities. To fill that gap, we developed and validated
a specific, multilingual Cough and Sputum Assessment Questionnaire (CASA-Q) that evaluates
clinical symptoms and their impact on patients with COPD or chronic bronchitis.
In a three-country validation study (nZ 671), there was adequate internal consistency
(Cronbach’s alphas, 0.80e0.91) and testeretest reliability (correlation coefficients> 0.70)
for the CASA-Q. The cough impact and sputum impact domains correlated with the SGRQ
impact domain and SGRQ total score, as did the cough impact domain with the SF-36 social
functioning domain. The cough symptom and sputum symptom domains correlated with spu-
tum wet weight (p< 0.05; rZ0.56), but not with cough recordings. The mean CASA-Q cough
symptom and sputum symptom domain scores indicated responsiveness towards both worse
and improved symptoms, whereas the impact domains scored already in the upper third of
the scale range, indicating the need for further improvement of its properties. Differences720 0001; fax: þ1 617 720 0004.
apivalues.com (B. Crawford).
8 Elsevier Ltd. All rights reserved.
1546 B. Crawford et al.in the CASA-Q domain scores by smoking status (current vs. former smokers) were highest for
cough symptoms and lowest for sputum impact. These data indicate that the CASA-Q may be
a useful measure of cough and sputum production, and their impact in patients with COPD
and/or chronic bronchitis. Further validation will need to assess the responsiveness of the
CASA-Q to changes in symptoms.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Airway mucus hypersecretion is a phenotype associated
with several chronic inflammatory airway diseases, e.g.,
asthma and chronic bronchitis. The term ‘‘chronic bronchi-
tis’’ originated from a clinical diagnosis usually defined by
cough and sputum production on most days during three
consecutive months for more than two successive years.1
According to the current nomenclature used for chronic
obstructive airway diseases, chronic obstructive bronchitis
is subsumed under the disease entity of chronic obstructive
pulmonary disease (COPD), which also includes emphy-
sema.2 COPD is characterized by airflow limitation that is
not fully reversible, and is usually progressive. Sputum
expectoration has been found to correlate with the decline
in lung function in patients with COPD,3 and a recent study
indicated that the presence of cough and phlegm might
identify subjects with a high risk of COPD.4
Cough and sputum production may be important
contributors to patients’ impaired well being and function-
ing in patients with COPD and chronic bronchitis. These
symptoms and their impacts are therefore compelling
outcomes to investigate from a patient perspective. Cur-
rently, there is no instrument that comprehensively mea-
sures cough and sputum symptoms and their impact on
everyday life, specifically in this patient population. Sev-
eral instruments have been developed to assess cough,
including the Leicester Cough Questionnaire (LCQ), the
Breathlessness, Cough and Sputum Scale (BCSS), the Cough-
Specific Quality of Life Questionnaire (CQLQ), the Chronic
Bronchitis Symptoms Assessment Scale (CBSAS), and the
Chronic Cough Impact Questionnaire (CCIQ). The LCQ was
developed for patients with chronic cough, however, it is
unknown if any COPD patients were included in the de-
velopment and therefore, it is not known if this question-
naire would be applicable to a COPD population.5
Additionally, the LCQ focuses on three domains (physical,
psychological and social), and not on sputum production
or its impact. The BCSS was developed for COPD patients
to track the severity of respiratory symptoms.6 This
three-item questionnaire was well developed, but asks
solely about the frequency of cough rather than its impact
making it less desirable if the goal is to assess both. The
CQLQ was developed for patients with chronic cough, but
lacked patient input during the development of the instru-
ment.7 The demographics of patients during the validation
process included mostly post-nasal drip syndrome (81%) and
gastro-esophageal reflux disease (72%), with less than 6% of
the sample having chronic bronchitis. The CBSAS is well de-
veloped and validated, but is primarily focused on severity
of cough and associated symptoms, such as shortness of
breath, and lacks an adequate assessment of sputum and
its impact.8 The CCIQ was developed for patients withchronic cough, primarily focusing on post-nasal drip syn-
drome and gastro-esophageal reflux disease.9 Given the
lack of focus on cough and sputum impact, the aforemen-
tioned questionnaires were not appropriate for use in trials
assessing cough and sputum production in patients with
COPD or chronic bronchitis.
This study set out to develop and validate a specific
Cough and Sputum Assessment Questionnaire for patients
with chronic (obstructive) bronchitis, especially in accor-
dance with the relevant guidelines set forth by regulatory
agencies.10,11 These guidelines define a Patient-Reported
Outcome (PRO) as the ‘‘measurement of any aspect of a pa-
tient’s health status that comes directly from the patient
(i.e., without the interpretation of the patient’s responses
by a physician or anyone else)’’.11 In order for an instru-
ment to be considered well developed, the new guidelines
have specified several key points. The development of the
instrument must include patient involvement to assist in
developing the concepts to be measured or, as the guide-
lines infer, the question generation process would be
incomplete. A wide range of patients should be included
in the development of a questionnaire to ensure a represen-
tative sample and variations in population characteristics.
Following the development of the questions, it is important
to review these questions with patients to ensure their clar-
ity and relevance. A questionnaire is not considered valid
until the statistical properties have been tested. The new
guidelines direct researchers on the validation steps to
ensure the measurement properties are adequate for use
in clinical trials. Regulatory agencies want to be sure the
questionnaire reliably measures the concepts it was de-
signed to measure. It should be noted, however, that the
statistical testing of the questionnaire should guide the de-
velopment and not dictate which items remain in the ques-
tionnaire. Relevance to the patient and clinical importance
should always be considered. Following these guidelines,
we aimed to develop the questionnaire simultaneously in
several languages from diverse geographical regions to en-
sure maximal cultural applicability.
Methods
Development phase
Conceptual framework
Literature and Patient-Reported Outcome (PRO)
questionnaire reviews were conducted to assess the impact
of cough and sputum on patients’ lives and identify/
appraise existing instruments. The data indicated that
existing questionnaires did not satisfy all criteria (i.e.,
they were nonspecific for patients with COPD and chronic
bronchitis, and/or had no patient involvement in question-
naire development). Thus, we developed a new PRO
CASA-Q for cough and sputum assessment 1547questionnaire by drafting a conceptual model to capture
relevant elements in assessing of cough and sputum in
patients with COPD and chronic bronchitis.
The aim was to develop the questionnaire in seven
languages (French, German, Spanish for Spain and United
States (US); Japanese and English for US and United
Kingdom (UK)) in five countries (see below) for diverse
geographical regions (Europe, Japan and US). The concep-
tual model was reviewed by a panel of clinicians from these
countries, to ensure the clinical relevance and content of
the questionnaire, and preclude potential cultural bias.
Initial patient interviews and expert review
Following the development of the conceptual framework,
patients in all five countries encompassing seven languages
were recruited (nZ 41). The selection criteria included: his-
tory of chronic bronchitis (i.e., daily sputum production for
at least threemonths in two consecutive years); over 40 years
of age; stable symptoms within four weeks prior to study
entry (i.e., amount and color of daily sputum unchanged);
and history of at least five pack-years of smoking. Exclusion
criteria included: concurrent respiratory diseases (e.g., his-
tory of asthma, atopy, allergic rhinitis, cystic fibrosis, clinical
diagnosis of bronchiectasis, and thoracotomy with pulmo-
nary resection); significant cardiac or respiratory disease
(e.g., active tuberculosis, bronchial cancer, and cardiac fail-
ure); hepatic or renal failure; and acute exacerbation or
acute infection within four weeks before study entry.
Patients signed informed written consent approved by the
respective institutional review boards (IRBs) and Indepen-
dent Ethics Committees. Using a semi-structured interview
guide, trained interviewers conducted face-to-face inter-
views in Germany and Spain (nZ 5 each), France (6), Japan
(10), and the US (15). Written transcripts from taped inter-
views and verbatim subject comments were then analyzed.
The identified concepts and selected quotes were summa-
rized for item generation in the cough and sputum question-
naire, which was then developed simultaneously in US
English, French, German, Japanese and Spanish by con-
trolled simultaneous development (items developed in
each language yielded preliminary, draft questionnaires
that were conceptually equivalent across all languages).
Draft questionnaires were generated in five languages and
provided to the same clinical experts who assisted in the con-
ceptual framework development. All reviews were con-
ducted in their respective native languages to ensure the
clinical relevance and importance of the questionnaires’
concepts. Expert review and commentary were utilized to
amend the questionnaire. The questionnaire was then adap-
ted toUKEnglish andUS Spanish fromtheUS English andSpain
Spanish versions, respectively.
Cognitive debriefing and questionnaire amendment
For cognitive debriefing of the draft questionnaires, trained
interviewers conducted face-to-face interviews using
a structured interview guide with another set of 40 patients
in France, Germany, UK, Spain and Japan (nZ 5 each);
Spanish-speaking patients in the US (5), and English-
speaking patients in the US (10). The purpose was to
ensure: (1) the relevance of concepts covered by the draft
questionnaire, (2) the comprehensiveness/understandabil-
ity of the questionnaire itself, and (3) the applicability/acceptability of each items. Following systematic analyses
of the interview transcripts, final changes were imple-
mented, and the version for the initial validation was
produced in seven languages.
Validation phase
Patients
After relevant IRB and Independent Ethics Committee
approval, an initial cross-sectional validation study was
conducted in Germany, France and the US with the re-
spective language versions of the CASA-Q (US English for US
only). After written informed consent, subjects were
enrolled into four groups: (1) healthy subjects, (2) COPD
(GOLD Stages 2e4) without sputum expectoration in the
past four weeks, (3) COPD (GOLD Stages 2e4) who expec-
torated at least a tablespoon of sputum/day for the past
four weeks, and (4) chronic bronchitis without obstruction
who expectorated at least a tablespoon of sputum/day for
the past four weeks. Inclusion/exclusion criteria mirrored
that of the development phase (see above).
Other subjective measures
Other measures were co-administered during validation,
e.g., the Medical Outcomes Study 36-item Short Form
Health Survey (SF-36), St. George’s Respiratory Question-
naire (SGRQ), and the Medical Research Council Dyspnea
Scale (MRC-Dyspnea Scale). The SF-36 is a generic health-
related quality of life instrument,12 consisting of eight
domains (e.g., physical functioning, role-physical, bodily
pain, general health, vitality, social functioning, role-
emotional, and mental health), with each generating
a transformed score of 0e100 (0, worst; 100, best).13 Two
summary scores can also be calculated. The SGRQ measures
the impact of lung disease on health-related quality of life
and well being, and responses to its 50 items can be aggre-
gated into both overall and three sub-scores for symptoms,
activity, and impact. Responses are weighted and scored
from 0 to 100 (0, worst; 100, best). The SGRQ is reported
to be valid and reliable in COPD patients.14,15 The MRC-
Dyspnea Scale consists of five grades of breathlessness
(grade 1: not troubled by breathlessness except on strenu-
ous exertion, grade 2: short of breath when hurrying on the
level or walking up a slight hill, grade 3: walk slower than
people of the same age on the level because of breathless-
ness, grade 4: stop for breath after walking about 100 yards
on the level, and grade 5: too breathless to leave the house
or breathless after undressing).16 The MRC was primarily
used as a clinical assessment as it was not expected to be
highly correlated with the CASA-Q.
A subset of patients (nZ 172) from all three countries
completed the CASA-Q for testeretest reliability one week
later. They also completed the Patient Global Impression of
Improvement (PGI-I) scale and a daily symptom diary for
the intervening week of the first and second visits. The PGI-
I assesses symptom change since a previous visit on a scale
ranging from 1 (very much better) to 7 (very much worse).
Objective measures
A subset of patients with COPD or chronic bronchitis in the
US underwent 24-h cough monitoring with an ambulatory
cardiorespiratory monitoring system (LifeShirt,
1548 B. Crawford et al.VivoMetrics, Ventura, CA). The system incorporates
a unidirectional contact microphone and respiratory induc-
tance plethysmography for the recording of respiratory and
abdominal movements.17 Furthermore, these patients col-
lected spontaneous 24-h sputum specimen on two separate
occasions. Sputum was collected at home in a sterile sealed
container and brought in on wet ice. Patients swallowed
saliva and then expectorated all secretions they were
able to. Sputum was visually separated from saliva and
stored in separate aliquots of 150 ml in dehydration-
protected O-ring containers. All specimens were stored at
70 C until sent to the lab for analysis of wet and dry
weight.
Validation analyses
A series of analyses assessed the measurement properties
of the CASA-Q, and its validity and reliability. Other goals
included assessing the need for item reduction and
generating a scoring algorithm. Item reduction might be
necessary due to missing data or limited use of response
options indicating that an item is irrelevant or difficult to
answer. Multitrait analyses18,19 investigated the question-
naire’s domain structure and grouping of items into their
hypothesized domain. Also, item convergent validity was
analyzed, i.e., the correlation between each item and its
hypothesized domain (Pearson’s Correlation Coefficients
should be >0.40).18 Item discriminant validity compares
the Pearson’s Correlation Coefficient between each item
and its hypothesized domain, and to all other domains;
items should correlate higher with their hypothesized
domain than with others.20 Reliability was assessed by
measuring internal consistency using Cronbach’s alpha
coefficient for each domain. Cronbach’s alpha coefficient
should be >0.70.20 Testeretest reliability was assessed by
analyzing the CASA-Q responses collected one week apart
in stable subjects, defined as those who responded ‘‘no
change’’ on the PGI-I after one week; and additionally in
a sensitivity analysis those responding ‘‘no change,’’ ‘‘a lit-
tle better,’’ or ‘‘a little worse’’. The recommended thresh-
old for an acceptable correlation is an Intraclass correlation
(ICC) of >0.70 (ShrouteFleiss reliability single score statis-
tic).21 Concurrent validity was measured by correlating the
CASA-Q domain and SF-36/SGRQ scores. This criterion was
achieved if a significant (p< 0.05) correlation coefficient
of 0.40e0.70 was observed between a CASA-Q domain score
and concurrent measure (higher correlations indicate re-
dundancy and are undesirable). Pre-specified analyses
based on the similarities of underlying concepts included:
(1) correlations between the SF-36 social functioning
domain and the CASA-Q impact domains; and (2) the
SGRQ domains and the CASA-Q domains. For clinical valid-
ity, Spearman’s correlation coefficients were calculated
between the CASA-Q domain scores and clinical measures
for cough frequency and sputum production. Known-
groups’ differences (e.g., discriminant properties) for
CASA-Q domain scores for the four subject groups were in-
vestigated by comparing the CASA-Q mean domain scores.
It is expected that healthy subjects would demonstrate
better scores than the other groups. In addition, patients
without sputum production should have higher scores
(i.e., less symptoms, less impact) on the sputum domains.Results
Development phase
The conceptual model assumed that patients could
distinguish between cough and sputum, but that these
symptoms may be linked (i.e., cough to expel sputum). For
both symptoms investigated, two concepts were identified
that measure complementary aspects, namely the descrip-
tion of the symptom and its impact on daily functioning.
There were other items that arose from the interviews
(e.g., fear, seasonal cough), however, as they were not
related to the symptom or impact, they were not included
in the draft questionnaire. After item generation, the
questionnaire consisted of 34 items which were derived
from patient statements from each country, several of
which were redundant but were included to clarify prefer-
ence for wording. Following cognitive debriefing and
clinical expert review as described in the Methods section,
the questionnaire consisted of 25 items in the four domains
of the conceptual model: the cough symptom domain
(three items), the cough impact domain (12 items), the spu-
tum symptom domain (three items), and the sputum impact
domain (seven items). The development process yielded
seven language versions that should be equally applicable
to patients with chronic (obstructive) bronchitis in the
countries included in the development. The recall period
of the questionnaire is the ‘‘last 7 days’’. This recall period
was selected because of the chronic nature of chronic bron-
chitis and COPD and the fact that important impacts do not
happen on a daily basis but will likely be covered within one
week. The response continuum was evaluated on 16 of the
34 original items to evaluate patient preference and ease of
responses, resulting in response options that range from
‘‘never’’ to ‘‘always’’ or from ‘‘not at all’’ to ‘‘a lot/ex-
tremely’’ as applicable; each type using five categories.
The questionnaire has one page of simple instructions and
is paper-based.
Validation phase
Subject characteristics
A total of 671 subjects were recruited into the
psychometric validation study. A detailed patient flow
chart can be found in Fig. 1. Subjects’ disposition by sub-
group is detailed in Table 1. Disease duration was between
9 and 10 years in the three patient groups, with smoking
history longest in the two COPD groups. The vast majority
of the healthy subjects had MRC grade 1, whereas two-third
of the COPD patients had grades 2 and 3.
Item reduction
The percent of missing responses on the individual items
ranged from 0.0% to 2.1%, which did not indicate items
should be deleted based on the missingness criterion.
Several items concerning cough symptoms (hurting ones
throat or chest, headaches, tired after coughing) had each
at least 25% of subjects responding with the lowest re-
sponse category (i.e., floor effect). Another item about
cough impact (avoid going to public places) also had a large
floor effect (at least 64% of subjects). The corresponding
Enrolled
671
Germany
196
Ineligible: 29
Protocol violators: 68
Analysed
574
France
215
US
163
47* 68* 57*
42**
*Subset in test-retest sample 
**Subset in cough and sputum sample
Group 1: 31
Group 2: 57
Group 3: 58
Group 4: 17
Group 1: 27
Group 2: 53
Group 3: 56
Group 4: 60
Group 1: 26
Group 2: 60
Group 3: 66
Group 4: 63
Group 1: Healthy
Group 2: COPD w/o sputum
Group 3: COPD w sputum
Group 4: Chronic bronchitis with sputum
Figure 1 CASA-Q validation study: subject flow chart.
CASA-Q for cough and sputum assessment 1549sputum item had a similar response pattern (at least 57%
scored with lowest category). It was decided to retain these
two items despite large floor effects as they represent
a major impact on the patient’s life, but is not likely to be
realized unless the patient is in a severe state. This would
extend the continuum of impact being covered as well as
accounting for patients’ discussions around the importance
of these items. Due to the clinical importance of knowing
the patient is avoiding activities due to their coughing and
sputum expectoration, these items will be further tested,Table 1 CASA-Q validation study subject characteristics by sub
Group 1:
healthy
G
C
n 84 1
Age (mean years, SD) 51.3 (9.36) 6
Male/female (n) 26/58 1
Smoking status (n/%)
Never smoker 46 (54.8) e
Ex-smoker 38 (45.2)
Current smoker e
Smoking (mean pack-years, SD) 4.4 (2.48) 4
Disease duration
(mean years, SD)
e
Pre-bronchodilator FEV-1 (mean, in liters, SD) 3.1 (0.85)
Post-bronchodilator FEV-1 (mean, in liters, SD) e
MRC grade (n/%)
Grade 1 66 (94.3)
Grade 2 2 (2.9)
Grade 3 1 (1.4)
Grade 4 1 (1.4)
Grade 5 ebut are subject to removal if they do not perform
adequately. In finalizing the CASA-Q item reduction pro-
cess, it was decided to remove items with a pronounced
floor effect, or high itemeitem correlations as this would
indicate items are not capturing unique aspects of cough
and/or sputum symptoms and impact. It was decided that
three items from the cough symptom domain would be
therefore removed (hurting throat, hurting chest, head-
ache). Another item from the cough symptom domain was
removed (worried about coughing bouts) due to highgroup
roup 2:
OPD w/o sputum
Group 3:
COPD with sputum
Group 4:
chronic bronchitis
70 180 140
6.1 (9.45) 65.1 (10.06) 57.0 (12.43)
11/59 114/66 83/57
e e
128 (75.3) 105 (58.3) 56 (40.0)
42 (24.7) 75 (41.7) 84 (60.0)
9.6 (27.12) 50.0 (23.16) 35.2 (18.67)
9.5 (6.14) 10.2 (7.06) 8.5 (7.19)
1.3 (0.50) 1.3 (0.53) 2.9 (0.80)
1.4 (0.52) 1.4 (0.55) 3.0 (0.82)
35 (21.2) 29 (16.8) 77 (55.4)
54 (32.7) 61 (35.3) 43 (30.9)
56 (33.9) 56 (32.4) 15 (10.8)
18 (10.9) 25 (14.5) 4 (2.9)
2 (1.2) 2 (1.2) e
Table 2 Multitrait analysis of CASA-Q items: descriptive statistics and Pearson itemedomain correlations corrected for
overlapa (item reduced model)
Domain Item description Mean SD Pearson itemedomain correlations
COUS COUI SPUS SPUI
Cough symptoms (COUS) In morning 2.66 1.10 0.72 0.60 0.57 0.54
During the day 2.91 0.91 0.75 0.62 0.53 0.52
Coughing bouts 2.32 1.03 0.71 0.71b 0.55 0.61
Cough impact (COUI) Tired after coughing 1.99 1.10 0.53 0.72 0.41 0.58
Shortness of breath
due to cough
2.41 1.15 0.59 0.71 0.45 0.56
Annoyed by cough 2.48 1.27 0.69 0.70 0.54 0.65
Avoid going
to public places
1.45 0.89 0.38 0.59 0.26 0.51
Usual activities interrupted 1.75 0.97 0.51 0.72 0.41 0.62
Conversations with
others interrupted
2.03 0.94 0.58 0.71 0.45 0.62
Sleep interference 1.97 1.07 0.60 0.71 0.47 0.60
Bothering other people 2.20 1.20 0.61 0.76 0.50 0.68
Sputum symptoms (SPUS) Thickness 2.49 1.11 0.56 0.48 0.74 0.65
Frequency 2.95 1.20 0.61 0.46 0.67 0.65
Difficulty of bringing up 2.31 1.18 0.43 0.51 0.54 0.69b
Sputum impact (SPUI) Difficulty to breathe 2.22 1.12 0.58 0.61 0.72b 0.72
Annoyed by phlegm 2.34 1.27 0.59 0.64 0.71 0.75
Avoid going
to public places
1.44 0.83 0.34 0.58 0.39 0.59
Usual activities interrupted 1.94 1.02 0.52 0.67 0.60 0.75
Interfere with
ability to speak
1.85 0.95 0.47 0.58 0.57 0.71
Bothering other people 2.33 1.30 0.53 0.68 0.71 0.76
a ‘Healthy’ subject group not included in analysis; correlation corrected for overlap (relevant item removed from its scale for
correlation).
b Less than desirable item discriminant validity: item correlation with competing domain is significantly higher or comparable to des-
ignated domain.
1550 B. Crawford et al.correlation with an item in the cough impact domain
(annoyed by coughing). One item in the sputum impact
domain correlated highly with another item in this domain,
which indicated redundancy (interruption of conversation;
interference with ability to speak), and was therefore
deleted. Therefore, after item reduction process the re-
vised CASA-Q included 20 items; three per each symptom
domain, and eight and six in the cough and sputum impact
domains, respectively.
Country-related specificities
The distributions of responses on the remaining items were
similar between countries (excluding the healthy subjects
from the analysis population). Overall, German subjects
tended to report cough and sputum symptoms and impact
items as being slightly worse. For example, German sub-
jects tended to report having more cough in the morning
and during the day compared to subjects in the US or
France. Subjects in Germany also reported being more
annoyed by their cough (13.6% extremely annoyed) than
subjects in the US (8.3%) or France (1.1%). Bringing up
phlegm often or always was reported 46.2% in German
subjects, whereas subjects in the US and France only
reported this 32.6% and 25.2%, respectively. Similar
response patterns were seen for difficulty breathing dueto phlegm (German subjects reporting often or always
22.5% of the time; US and France 9.1% and 10.8%, re-
spectively). These differences are reflected in 28.5% of
German subjects reporting being often or always annoyed
by their phlegm. This number is higher than in US and
France (18.2% and 15.8%, respectively).
Item convergent and discriminant validity
All cough items correlated higher with their assigned
domain than any other domain except one cough item
with a correlation coefficient of 0.71 for each cough
domain, symptom and impact (Table 2). For the sputum
domains, two items had higher or the same correlation co-
efficient for the complementary sputum domain. Given the
face validity of the three identified items that did not
correlate highest with their hypothesized domain, it was
decided to leave the items within their respective domain.
Overall, the domain structure of the CASA-Q was supported
by this analysis. All items on the CASA-Q correlated with
their respective domain at a 0.40-level or greater, indicat-
ing acceptable convergent validity.
Scoring algorithm
All items were rescored from 1e5 to 0e4, and then reverse
scored such that better responses had higher scores. Within
Table 4 Testeretest reliability: intraclass correlations
(ICCs) of CASA-Q domain scores in stable subjects (based
on PGI-I)a
Intraclass
correlation
(nZ 118)
PGI-I: ‘‘no
change’’
Intraclass correlation
(nZ 157)
PGI-I: ‘‘no change’’
and ‘‘little
worse/better’’
Cough symptoms 0.77 0.74
Cough impact 0.88 0.84
Sputum symptoms 0.80 0.80
Sputum impact 0.82 0.80
a ‘Healthy’ subject group not included in analysis; Shroute
Fleiss reliability ICC.
CASA-Q for cough and sputum assessment 1551each domain, items were summed and rescaled using the
following algorithm: (sum rescored items)/(range of re-
scored item sum) 100. This resulted in CASA-Q domain
scores that range from 0 to 100, with higher scores associ-
ated with fewer symptoms/less impact due to cough or
sputum.
Psychometric validation of the item-reduced CASA-Q
All domains had acceptable internal consistency reliability
considering Cronbach’s alphas ranging from 0.80 to 0.91
(Table 3). Testeretest reliability in ‘‘stable patients’’
demonstrated adequate performance as all correlations
were above 0.70 (Table 4). Concurrent validity was mea-
sured calculating correlations of the CASA-Q domain
scores with the SF-36 domain scores (pre-specified:
correlation between SF-36 social functioning and CASA-Q
impact domains) and the three SGRQ domain (pre-speci-
fied) and total scores (Tables 5a and 5b). All comparisons
but one (CASA-Q cough symptoms vs. SGRQ activities)
were statistically significant, however, only four compari-
sons met the pre-specified criteria, i.e., cough and spu-
tum impact domains of the CASA-Q correlated >0.40
with the SGRQ impact domain and the SGRQ total score.
For all SGRQ domain correlations, the CASA-Q impact do-
mains showed higher correlations with the SGRQ domains
than the CASA-Q symptom domains. For the pre-specified
correlation between the social functioning domain of the
SF-36 and the CASA-Q impact domain, only cough impact
but not sputum impact reached the >0.40 threshold.Table 3 Multitrait analysis: CASA-Q internal consistency
reliability coefficients (Cronbach’s alpha), domain floor
and ceiling effects, and domain successa
Domain Cronbach’s
alphab
Floorc (%) Ceilingc (%) Itemedomain
correlation
significantly
higher (%)
Before item reduction
Cough
symptoms
0.85 3.2 1.1 88.9
Cough
impact
0.92 12.0 0.0 100.0
Sputum
symptoms
0.80 13.3 0.4 88.9
Sputum
impact
0.91 18.3 0.0 95.2
After item reduction
Cough
symptoms
0.85 3.2 1.1 100.0
Cough
impact
0.91 13.3 0.0 100.0
Sputum
symptoms
0.80 13.3 0.4 88.9
Sputum
impact
0.89 19.5 0.0 94.4
a ‘Healthy’ subject group not included in analysis.
b Desired alpha> 0.70.
c Desired floor/ceiling effect< 20%.Clinical validity
Clinical validity was investigated by correlating the CASA-
Q domain scores to the clinical measures derived from
sputum collections and cough recordings (Table 6). The
correlation coefficients for cough recordings did not
meet the pre-specified criteria of >0.40. Among the pe-
riods of the day analyzed, the highest correlations were
seen in the morning (defined as 5e9 am). The cough and
sputum symptom domains demonstrated all significant
(p< 0.05) correlations with the total sputum wet weight.
The correlation was strongest for sputum symptoms
(rZ0.5635).
Discriminant properties
For the two patient groups with sputum, the cough and
sputum symptom domains were approximately half of the
maximum possible score (49e53), indicating possible re-
sponsiveness of the scores towards worse and improved
symptoms. However, in both these groups, the impact
domains for cough and sputum were between 64 and 74,
indicating that in further validation steps, items with high
floor effects should be scrutinized and will be candidates
for deletion (Fig. 2). Among the patient groups, those with
COPD without sputum systematically scored higher than
COPD patients with sputum and those patients with chronic
bronchitis. The healthy group scored for all domains be-
tween 94 and 99, close to the maximum (‘normal’) score
of 100. Additionally, CASA-Q domain scores by smoking sta-
tus were investigated using data from the three patient
groups (Fig. 3). Differences between the mean scores
were highest for the cough symptom domain and lowest
for the sputum impact domain.
Domain structure
Inter-scale correlations yielded moderate to high correla-
tions between the four CASA-Q domains (Table 7), ranging
between 0.57 and 0.78; thus supporting the assumption of
interrelationship between cough and sputum symptoms
and their impact, but yet providing evidence for the need
to assess them in separate domains. The two cough domains
and the two sputum domains were each correlated among
themselves above 0.70, as was the case for the two impact
domains.
Table 5a Concurrent validity: correlations between CASA-Q and SGRQ domain scores (NZ 490) (item reduced model)a
CASA-Q
SGRQ Cough symptoms Cough impact Sputum symptoms Sputum impact
Symptoms Correlation 0.1701 0.2283 0.1964 0.2810
P-value 0.0003 <0.0001 <0.0001 <0.0001
Impact Correlation 0.3157 0.5404 0.3363 0.4749
P-value <0.0001 <0.0001 <0.0001 <0.0001
Activities Correlation 0.0422 0.2705 0.1148 0.2176
P-value 0.3768 <0.0001 0.0160 <0.0001
Total Correlation 0.2461 0.4912 0.2905 0.4303
P-value <0.0001 <0.0001 <0.0001 <0.0001
Pre-specified correlations: SGRQ domain scores with CASA-Q domain scores.
a Desired correlation between 0.40 and 0.70. Correlations that met this criterion are in bold.
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Following the principles set forth in new regulatory
guidelines, the CASA-Q was developed to allow for a core
set of cross-culturally relevant concepts to be included in
the questionnaire. After being simultaneously developed in
five countries and seven languages, the CASA-Q had 25
items assessing four hypothesized concepts (prior to psy-
chometric validations): cough symptoms, cough impact,
sputum symptoms, and sputum impact. It was then
validated in three countries following the strict process
recommended by current guidelines.
Establishing the psychometric properties of the CASA-Q
is an essential part of the questionnaire’s development. If
such measures are to be a useful tool in both the clinical
and research settings they must have good reliability and
validity and be sensitive to change. The results reported
here established the psychometric integrity of the newly
developed patient self-reported measure for assessingTable 5b Concurrent validity: correlations between CASA-Q an
CASA-Q
SF-36 domain Cough symptoms
Physical functioning Correlation 0.0143
P-value 0.7651
Role limitations
due to physical problems
Correlation 0.1336
P-value 0.0050
Role limitations
due to emotional health
Correlation 0.1699
P-value 0.0003
Social functioning Correlation 0.2132
P-value <0.0001
Bodily pain Correlation 0.1952
P-value <0.0001
Mental health Correlation 0.1737
P-value 0.0003
Vitality Correlation 0.1575
P-value 0.0009
General health Correlation 0.1481
P-value 0.0018
Pre-specified correlations: SF-36 social functioning to CASA-Q impact
a Desired correlation between 0.4 and 0.7. Correlations that met thcough and sputum symptoms and impact. Establishing the
construct and clinical validity, along with reliability, of an
instrument in the targeted population is essential to de-
claring an instrument valid for use in trials or clinical
practice.
The CASA-Q was validated using data from an
independent study in three countries, allowing the evalu-
ation of culturally biased questions. Initial item reduction
removed five items due to high floor effects and item
redundancy, resulting in a 20-item questionnaire for psy-
chometric evaluation. Following the reduction of items to
produce a shorter, more valid questionnaire, the remaining
items were categorized into their respective scale based on
their concept. These scales were evaluated with respect to
their construct (how well the items fit together into
a domain), reliability and validity.
The final set of items demonstrated adequate response
distributions, however, some items remained skewed to-
wards the lower end of the response continuum. Internald SF-36 domain scores (NZ 490) (item reduced model)a
Cough impact Cough symptoms Sputum impact
0.2633 0.0780 0.2038
<0.0001 0.1024 <0.0001
0.3592 0.1985 0.3298
<0.0001 <0.0001 <0.0001
0.3295 0.1848 0.3022
<0.0001 0.0001 <0.0001
0.4166 0.1973 0.3592
<0.0001 <0.0001 <0.0001
0.3197 0.2068 0.2963
<0.0001 <0.0001 <0.0001
0.3392 0.1976 0.3080
<0.0001 <0.0001 <0.0001
0.3470 0.2178 0.3015
<0.0001 <0.0001 <0.0001
0.3150 0.2062 0.3206
<0.0001 <0.0001 <0.0001
domains.
is criterion are in bold.
Table 6 Clinical validity: Spearman’s correlation coefficients for CASA-Q domain scores and sputum measures (nZ 39) and
cough frequency measures during several time periods (nZ 32), respectively (item reduced model)
CASA-Q domain Sputum wet
weight
Sputum volume
before mucous
separation
Sputum volume
after mucous
separation
Cough
morninga
Cough dayb Cough nightc Cough 24 h
Cough symptoms 0.4683 0.3184 0.2703 0.2408 0.0618 0.2165 0.1416
Cough impact 0.3020 0.2489 0.2672 0.2743 0.1010 0.1939 0.1654
Sputum symptoms 0.5635 0.1666 0.2843 0.2136 0.0440 0.1425 0.0751
Sputum impact 0.3800 0.2890 0.1884 0.1952 0.0421 0.1233 0.1032
Pre-specified desired correlation: >0.40. Correlations that met this criterion are in bold.
a Morning: 5 ame9 am.
b Day: 9 ame22 pm.
c Night: 22 pme5 am.
CASA-Q for cough and sputum assessment 1553consistency reliability coefficients were 0.80 for each
domain, exceeding the recommended threshold of 0.70 for
an acceptable domain. Additionally, items correlated more
highly with their own domain than with other domains for
most items and all items correlated with their own domain
0.40, the recommended threshold.
The CASA-Q demonstrated adequate testeretest
reliability with all domains achieving a reliability coeffi-
cient greater than 0.70. Concurrent validity, however,
was not able to meet all of the pre-specified criteria. The
cough impact and sputum impact domains met the desired
0.40-level for correlations to the SGRQ impact domain and
total score. The symptom domains did not correlate well
with the SGRQ symptom domain indicating they are not
measuring the same concepts. The SF-36 social functioning
domain and the cough impact domain met the desired level
but the sputum impact domain fell short (rZ 0.3592).
Although it may have been desirable to correlate the
CASA-Q with a more specific questionnaire, the BCSS was
unavailable at the time of this study. Other questionnaires
had not been validated within a relevant, i.e., COPD and/orCOUS COUI SPUS SPUI
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Figure 2 Discriminant properties for CASA-Q domains for
subject groups. All differences between groups per domain sta-
tistically significant (c2 p-values< 0.0001). COUS: cough symp-
tom domain, COUI: cough impact domain, SPUS: sputum
symptom domain, SPUI: sputum impact domain. Bar indicates
standard deviation.chronic bronchitis, population and therefore were
considered inappropriate measures for this study, albeit,
potentially better measures for the symptoms. In measuring
symptoms through clinical parameters (i.e., sputum collec-
tion and LifeShirt), this direct relationship was sought.
Therefore, the use of broader measures, such as the SF-
36 and SGRQ, sought to capture the impact of these symp-
toms on the patient’s day-to-day activities.
These results indicate the usefulness of a measure
designed to focus on two important symptoms of COPD:
cough and sputum and their associated impact. Other ques-
tionnaires, such as the BCSS, are suitable for assessing the
occurrence of symptoms (both cough and sputum) on a daily
basis but do not capture the impact of these symptoms on
the patient’s life. Additionally, the use of a daily diary has
been the subject of recent research given the inherent
difficulties of using diaries, such as non-response, lost
diaries, illegible writing, etc. Juniper et al.22 compared
the validity and utility of using a daily diary vs. a one-
week recall questionnaire to assess asthma control. Both
questionnaires were worded similarly in an effort to isolate
the effects of the recall. The authors found the one-week
recall questionnaire to have better discriminative and eval-
uative properties than the diary, albeit, both were quiteCOUS COUI SPUS SPUI
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Figure 3 Discriminant properties for CASA-Q domains for ex-
smokers and smokers. ‘Healthy’ subject group not included in
analysis. COUS: cough symptom domain, COUI: cough impact
domain, SPUS: sputum symptom domain, SPUI: sputum impact
domain. Bar indicates standard deviation.
Table 7 CASA-Q inter-domain correlationsa (item reduced
model)
Domain COUS COUI SPUS SPUI
Cough symptoms (COUS) 1.00
Cough impact (COUI) 0.73 1.00
Sputum symptoms (SPUS) 0.63 0.57 1.00
Sputum impact (SPUI) 0.64 0.78 0.78 1.00
a ‘Healthy’ subject group not included in analysis.
1554 B. Crawford et al.similar. These results support the use of a one-week recall
questionnaire in place of daily assessments as there is less
of a burden on the patient and clinic staff and the results
are essentially the same.
The CASA-Q also evaluated the relationship with clinical
endpoints such as sputum weight and cough frequency. A
limitation of this study was that only a limited number of
patients underwent the clinical measures due to practica-
bility reasons and the inconvenience to undergo 24-h
monitoring. Nevertheless, both cough and sputum symp-
toms correlated above the desired level with sputum wet
weight. This indicated that patients may in fact be able to
note changes in their expectorated sputum volume. Cough
frequency as measured by an ambulatory monitoring device
was obviously only poorly associated with cough symptom
scores on the CASA-Q, and there were patients with more
than 1000 coughs/24 h as registered by the monitor who
scored to cough ‘never’ or ‘rarely’. This observation, how-
ever, was not unexpected as only a weak correlation
between objectively measured and reported cough fre-
quency has been described in patients with chronic
cough.23 Of note, current methodology to measure cough
objectively is neither validated nor is there any cough
monitor considered to be gold standard.24 In addition,
perception of cough intensity and frequency may relate
to factors other than what can be objectively measured
by cough monitors, such as general health status, underly-
ing lung function, other symptoms (e.g., dyspnea, sputum
production, and fatigue), as well as previous experience.
Because subjects may become accustomed to coughing,
their impressions of ‘‘how often’’ they cough may not cor-
relate with the cough counts. A sensory adaptation to a fre-
quent stimulus could be a possible explanation for this
obvious disconnect between measured and sensed cough.
Whether this will affect the responsiveness of the CASA-Q
cough domains remains to be elucidated. Therefore, the
CASA-Q met the recommended thresholds for validation
except for clinical validity in the cough domains.
In conclusion, the CASA-Q targets cough and sputum by
assessing these symptoms from two different approaches:
descriptively (e.g., frequency of the symptom, severity of
the symptom) and evaluating the impact of these two
symptoms on daily activities. Following additional valida-
tion, the CASA-Q will be the only questionnaire that was
derived directly from patients of various diverse cultures
and focused on not only the symptoms of cough and sputum
production, but also their impact on the patient’s life.
Further validation will have to investigate the responsive-
ness of the CASA-Q to interventional changes. Additionally,prior to using the CASA-Q as an outcome measure in clinical
trials, further items that remain as candidates for deletion
should be scrutinized.Acknowledgements
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